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Abstract
Background: FEV1 is universally used as a measure of severity in COPD. Current thresholds are based on expert opinion and
not on evidence.
Objectives: We aimed to identify the best FEV1 (% predicted) and dyspnea (mMRC) thresholds to predict 5-yr survival in
COPD patients.
Design and Methods: We conducted a patient-based pooled analysis of eleven COPD Spanish cohorts (COCOMICS). Survival
analysis, ROC curves, and C-statistics were used to identify and compare the best FEV1 (%) and mMRC scale thresholds that
predict 5-yr survival.
Results: A total of 3,633 patients (93% men), totaling 15,878 person-yrs. were included, with a mean age 66.469.7, and
predicted FEV1 of 53.8% (619.4%). Overall 975 (28.1%) patients died at 5 years. The best thresholds that spirometrically split
the COPD population were: mild $70%, moderate 56–69%, severe 36–55%, and very severe #35%. Survival at 5 years was
0.89 for patients with FEV1$70 vs. 0.46 in patients with FEV1 #35% (H.R: 6; 95% C.I.: 4.69–7.74). The new classification
predicts mortality significantly better than dyspnea (mMRC) or FEV1 GOLD and BODE cutoffs (all p,0.001). Prognostic
reliability is maintained at 1, 3, 5, and 10 years. In younger patients, survival was similar for FEV1 (%) values between 70%
and 100%, whereas in the elderly the relationship between FEV1 (%) and mortality was inversely linear.
Conclusions: The best thresholds for 5-yr survival were obtained stratifying FEV1 (%) by $70%, 56–69%, 36–55%, and
#35%. These cutoffs significantly better predict mortality than mMRC or FEV1 (%) GOLD and BODE cutoffs.
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Introduction
According to the Global Burden of Disease Study, in 2010
chronic obstructive pulmonary disease (COPD) was the third
leading cause of death worldwide and the ninth combining the
years of life lost or lived with disability (DAILYs).[1,2] COPD is
characterized by an airflow limitation and therefore spirometry
remains the essential test to diagnose the disease. Classically,
COPD severity has been graded by postbronchodilator FEV1
expressed as percent of predicted values (FEV1 %).[3] More
recently, several multidimensional indices have shown a better
survival prediction than the isolated FEV1 (%). These include the
original BODE index, which incorporates dyspnea measured with
the modified scale of Medical Research Council (mMRC), Body
Mass Index (BMI), FEV1, and exercise capacity assessed with the
6-minute walking distance (6MWD), as well as further modifica-
tions of this index, such as the BODEx (replacement of exercise
capacity with severe exacerbations).[4–6] Other multidimensional
prognostic indices are ADO (age, dyspnea, and FEV1), SAFE
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(quality of life measured by Saint George’s Respiratory Question-
naire, FEV1, and 6MWD), and DOSE (dyspnea, smoking status,
FEV1, and prior exacerbation history), among others.[7–9]
These indices have been constructed by adding different
variables – such as dyspnea, exercise capacity, exacerbations,
and age – to different categories of FEV1 values.[10] However,
Table 1. Demographic and clinical characteristics.
Number (SD) o %
Total
N=3,633
Alive
N=1,133
Dead
N=975 P HR CI 95%
Age 66.469.7 64.069.3 70.868.7 ,0.001 1.07 1.06–1.08
Gender (men) 3,389 (93.3) 1,040 (91.8) 953 (97.7) ,0.001 2.99 2.10–4.24
Smoking
Yes
Non
Former
26.9%
1.2%
71.9%
32.2%
0.4%
67.4%
20.8%
2.1%
77.1%
,0.001
0.001
,0.001
0.70
2.16
1 (Ref) &
(0.61–0.80)
(1.43–3.27)
–
Smoking
Packs/year
53.4626.5 55.4627.3 56.6626.8 0.101 1.01 (1.00–1.08)
Charlson Index 2.161.56 2.0061.38 2.4761.87 ,0.001 1.18 (1.14–1.23)
FVC (%) predicted 80.2622.6 88.6622.4 69.0620.7 ,0.001 0.97 (0.97–0.98)
FEV1 (%) predicted 53.8619.4 58.4620.6 44.6616.5 ,0.001 0.97 (0.96–0.97)
FEV1/FVC ratio 51.9611.8 51.3611.9 48.6612.0 ,0.001 0.97 (0.97–0.98)
Dyspnea (mMRC)
0
1
2
3
4
17.6%
33.7%
27.8%
23.7%
7.2%
18.8%
30.3%
31.4%
11.9%
7.6%
10.0%
24.4%
29.8%
21.5%
14.3%
,0.001
0.007
0.495
,0.001
,0.001
1 (Ref) &
1.24
1.79
2.68
3.25
–
(0.99–1.55)
(1.44–2.23)
(2.13–3.39)
(2.52–4.20)
Dyspnea (mMRC) # 1.5961.14 1.0361.20 2.0361.20 ,0.001 1.47 (1.40–1.54)
SGRQ* 42.7620.4 43.1620.2 47.6619.2 0.003 1.01 (1.01–1.02)
BMI (Kg/m2) 27.964.98 27.764.82 27.164.99 0.018 0.97 (0.96–0.98)
6-minute walking test
(meters)
397. 26130.5 409.26134.1 330.66124.4 ,0.001 0.996 (0.995–0.996)
Previous severe
exacerbations ¥
0.8961.82 0.9162.22 1.2861.86 ,0.001 1.07 (1.05–1.09)
Five-year mortality.
&Reference group;
# mMRC: dyspnea measured with the modified Medical Research Council;
*Health related Quality of life, measured with Saint George’s Respiratory Questionnaire;
¥Number of hospitalizations for COPD exacerbation in the previous year.
doi:10.1371/journal.pone.0089866.t001
Figure 1. Kaplan-Meier survival curves for different thresholds of FEV1 up to 15 years. Hazard ratios and 95% confidence intervals for
different thresholds of FEV1 :1) .80% reference group, 2) 60–79% (1.5; 1.06–2.11), 3) 50–79% (1.74; 1.25–2.43), 3) 41–59% (2.38; 1.7–3.32),4) 35–49%
(2.92; 2.1–4.07),5),40% (3.54; 2.53–4.95), 6),35% (5.18; 3.53–7.61)
doi:10.1371/journal.pone.0089866.g001
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different thresholds of FEV1 and dyspnea are used in different
staging systems and with different guidelines.[11–12] To date, the
most widely used cutoff values are those proposed by the Global
Obstructive Lung Disease (GOLD) and the ATS/ERS guidelines
(mild$80%, moderate 50–79%, severe 30–49% and very severe
,30%).[13] However, the BODE index uses the old ATS
standards ($65%, 50–64% 36–49% and #35%), while the DOSE
index uses a different cutoff (.50%, 30–49% and ,30%).[4,9] To
the best of our knowledge the majority of these classifications are
selected arbitrarily, based on cut-offs selected by expert opinion,
and it is not known which of them best discriminates among
different levels of mortality risk. Additionally, there are few studies
comparing the usefulness of FEV1 in different age groups and the
influence of dyspnea on survival assessment.[14–16]
The aim of the present study was to identify the best thresholds
for FEV1 (%) and dyspnea measured with the mMRC to predict 5-
yr survival in COPD patients, divided by subsets of age, using a
pooled-analysis of individual patient data from eleven Spanish
COPD cohorts (The COllaborative COhorts to assess Multicom-
ponent Indices of COPD in Spain-COCOMICS study).[10]
Methods
Ethics Statement
All participants gave their informed written consent to
participate, and their respective ethics committees approved each
study (Hospital Galdekao-Usarsolo, Navarra Clinic University
Hospital, Requena Hospital, Universitary Hospital Mu´tua de
Terrassa, Universitary Hospital of Valme and Universitary
Hospital Miquel Servet).
Study design
The COCOMICS study is a pooled-analysis of individual
patient-data from eleven Spanish COPD patient cohorts. The
methodology has been described in detail elsewhere.[10,17] Briefly
a common data set with age, gender, spirometry, comorbidity,
previous severe exacerbations, and follow-up among other
variables was provided by the principal investigator of each of
the participating cohorts.[6,18–26] Previous severe exacerbations
were defined as those requiring emergency room visit with or
without subsequent hospitalization during the previous year. All-
cause mortality at 5 years was defined as the primary outcome.
Postbronchodilator forced spirometry was performed according to
the guidelines of the American Thoracic Society/European
Respiratory Society consensus.[27] Dyspnea was assessed using
mMRC dyspnea scale.[5] Comorbidities were quantified by
means of the Charlson index, excluding COPD, without
adjustment for age.[28] All cohorts were previously published
although with different follow-up periods; the references of original
articles are available in the Online Appendix. All data were quality
controlled centrally, and a homogeneous template to translate all
coding was applied.
Statistical analysis
Qualitative variables were expressed as absolute and relative
frequencies, while quantitative variables were summarized as
mean and standard deviation in the case of symmetry, and median
otherwise. Comparison among continuous variables was made
using the robust means comparison Student-Welch test, under
symmetry, and the non-parametric Mann-Whitney U test
otherwise. The Fisher exact test was used in order to check
independence among categorical variables. We focused all analyses
on time to death for all causes. Standard Cox semi-parametric
Figure 2. Spline inverse of the 5-yr hazard ratio of death to identify spirometry thresholds of severity (70%–55%–35%).
doi:10.1371/journal.pone.0089866.g002
Table 2. Area under the curve (AUC) to predict 1, 3, 5, and 10-
yr survival at different staging spirometry thresholds, dyspnea
levels (mMRC) and time.
YEARS 1 3 5 10
COCOMICS 0.643 0.650 0.657 0.654
GOLD 0.635 0.639 0.647 0.639
Old ATS (BODE) 0.643 0.650 0.653 0.649
mMRC (Dyspnea) 0.623 0.620 0.625 0.614
P 0.013 0.006 0.004 0.006
GOLD: Global Obstructive Lung Disease classification. ATS: American Thoracic
Society classification. BODE: Body Mass Index, Obstruction (measured with old
ATS classification), Dyspnea and Exercise. mMRC: Dyspnea measured with the
modified Medical Research Council scale.
doi:10.1371/journal.pone.0089866.t002
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proportional hazard models, all of them stratified by cohort, were
used to study time-to-death data.[29] This methodology does not
impose parametric restrictions on how the continuous covariate and
the studied outcome are associated. In addition, the goodness-of-fit
quality of the considered models was measured using the area under
the incidence/dynamic ROC curve [30], AUC. The R package
risksetROC, freely available in the R CRAN (www.r-project.org), was
used for developing the computations. All the comparisons between
the curves were performed using the L1-measure (given two functions,
f and g, the L1-measure is defined by L1(f,g) = # |f(t)2g(t)|dt). The
general Bootstrap Algorithm (gBA) [31] was used in order to
approximate the respective P-values. The gBA method allows
developing complex hypotheses preserving the original data structure
and without assuming any additional hypothesis (just the one
considered null). Finally, optimal % FEV1 and dyspnea thresholds
were computed for maximizing the AUC at five years follow-up. In a
first stage, the threshold which leads to the Youden index was
computed and then, on each one of the two resulting sub-populations
and with the same criteria, a new threshold was computed. In all
analyses, P-values below 0.05 were considered for statistical
significance. The free software R.2.15 was used for developing the
analysis.
Results
A total of 3,633 subjects with COPD (93% men) were included
in the analysis, totaling the experience of 15,878 person-years. The
mean age was 66.4 (SD 69.7). At study entry, smoking exposure
was substantial (53.4626.5 pack-years), with 71.0% former
smokers, and 27.9% current smokers. Most participants had
moderate to severe airflow limitation with a predicted FEV1 (%) of
53.8%619.4%, and a Charlson index of 2.161.5. Patients over 65
had significantly more comorbidities measured with the Charlson
index than young people (#64 years) [1.83 (1.44) vs. 2.17 (1.60);
p,0.0001].
The main characteristics of the population cohorts are
presented in Table 1. On average women were younger
(59.8611.0 years vs. 66.969.5 years) and more frequently current
smokers (43.3% vs. 26.8%) than men (both p,0.05). After 5 years,
975 (28.1%) subjects had died. A significantly greater mortality
was observed in older patients and women. Lower levels of FEV1
(%) and BMI, greater dyspnea, poorer quality of life measured
with the Saint George’s Respiratory Questionnaire (SGRQ),
shorter distance walked in 6 x9 walking-test, and severe
exacerbations of COPD during the previous year were also
associated with a statistically significant five-year increased
mortality (Table 1).
Mortality during short, medium and long-term follow-up – from
one to 10 years - was consistently associated with FEV1 (%)
(Figure 1, Table 2). The best FEV1 thresholds (%) in the entire
cohort to predict 5-year mortality were mild$70%, moderate 56–
69%, severe 35–55%, and very severe #35%. Figure 2 shows
graphically the risk of mortality at the different cutoffs of FEV1
(%). Of note, patients with an FEV1 (%) lower than 35% had a
hazard ratio (HR) for mortality that was 6 times higher than the
reference group with FEV1$75% [95% Confidence Interval (CI):
4.69–7.74].
The probability of survival at 5 years was 0.89 (95% C.I.:0.86–
0.92) in patients with higher levels of FEV1 (%) (.70%) in contrast
to 0.46 (95% C.I.:0.42–0.51) for patients with FEV1 (%) ,35%.
Kaplan-Meier curves for different thresholds of FEV1 (%) and 5-
year mortality in the present study compared with GOLD and old
ATS-BODE cutoffs are displayed in Figure 3.
For all comparisons, the predictive ability of the new cutoff
points was higher than that of the previous cutoffs used in the
GOLD document and slightly better than those used in the BODE
index (old ATS). Hazard Ratios and their 95%CI between the
different cutoffs of the COCOMIX study, GOLD, and BODE are
presented in Table 3. Prognostic reliability of new thresholds is
maintained at 1, 3, 5, and 10 years (Table 2).
The prognostic value of FEV1 (%) differed according to age. In
patients 65 or older, we observed an inverse progressive
Figure 3. Kaplan-Meier survival curves of time to death by different staging spirometry thresholds: A) new COCOMICS, B) GOLD,
and C) old-ATS/BODE.
doi:10.1371/journal.pone.0089866.g003
Table 3. 5-yr hazard ratios of death at different staging
spirometry thresholds.
Mild Moderate Severe Very severe P
GOLD .80%
1 (ref.)
51–80%
2.51 (1.83–3.44)
30–49%
5.06 (3.71–6.90)
,30%
7.83 (5.65–10.87)
,0.001
Old ATS
(BODE)
$65%
1 (ref.)
50–64%
1.95 (1.61–2.35)
36–49%
3.02 (2.53–3.62)
#35%
4.62 (3.87–5.53)
,0.001
COCOMIX $70%
1 (ref.)
56–69%
1.91 (1.51–2.41)
35–55%
3.40 (2.76–4.20)
#35%
5.57 (4.48–6.91)
,0.001
GOLD: Global Obstructive Lung Disease classification. ATS: American Thoracic
Society classification. BODE: Body Mass Index, Obstruction (measured with old
ATS classification), Dyspnea and Exercise. Hazard Ratios and 95% Confidence
Intervals between different cutoffs of the COCOMIX study, GOLD, and BODE
classifications.
doi:10.1371/journal.pone.0089866.t003
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relationship between mortality and lung function, while in
individuals younger than 64, mortality was similar in the interval
of FEV1% between 75% and 100%.
Among patients with lower levels of dyspnea (mMRC#1), overall
survival at 5 years was 75.6% (95% CI: 73.2–78.1), for those who also
had lower dyspnea an FEV1 (%).90% survival at 5 years was 92.1%
(95% CI: 86.5–98.1). In contrast, patients with higher levels of
dyspnea (mMRC$2) had a 5-year survival of 56.0% (95% CI: 53.3–
58.9). No differences existed in the predictive ability of FEV1 (%) by
gender. The relationship between FEV1 (%), age, gender and
dyspnea are graphically displayed in Figure 4.
Of note, comparisons between Kaplan-Meier curves for the
different levels of FEV1 (%) and dyspnea (Figure 5) showed that
FEV1 (%) was a significantly better predictor of survival than
degree of dyspnea (p,0.001). Similarly, the new cutoffs of FEV1
(%) were significantly better predictors of survival at 1, 3, 5, and 10
years than the levels of dyspnea measured with the mMRC
(Table 3) (Figure 5).
Discussion
The current study was conducted in a large sample of patients
over the entire spectrum of COPD severity with long-term follow-
up, and it shows that the proposed new spirometric thresholds to
predict 5-year mortality (mild$70%, moderate 56–69%, severe 35–
55%, and very severe#35%) were significantly better predictors of
survival than those used in the GOLD, and slightly better than those
used in the BODE index (old ATS). This improvement in predictive
capacity was also verified in both the short- and long-term follow-up
(1 to 10 years). The study design – a pooled-analysis of individual
patient-data from several cohorts – the large sample size and the
different degrees of severity of the patients in the different cohorts
guarantee a high external validity of the results.
Traditionally, lung function, measured with the FEV1 after a
bronchodilator test, has been the most widely recognized variable
associated with mortality in COPD. Furthermore, FEV1 is a good
predictor of mortality even in the general population, and it is also
considered the most important variable to evaluate the severity of
COPD.[32] In addition, the decline in FEV1 over time has been
used to evaluate the progression of the disease, although wide
individual variability exist.[33] Until the last decade, different
scientific societies and clinical guidelines had proposed different
thresholds of postbronchodilator FEV1 expressed as percentage of
predicted values to classify the severity of the disease. However
these cutoffs were selected for pragmatic and educational reasons
based on expert opinion, which explains the existing discrepancies
Figure 4. Spline inverse of the 5-yr hazard ratio for FEV1 and death, adjusted for: A) age, B) gender and C) dyspnea.
doi:10.1371/journal.pone.0089866.g004
Figure 5. Kaplan-Meier survival curves up to five years for different thresholds of A) FEV1 according to new COCOMICS and B)
mMRC. The quality of the models is measured from the AUC in the incidence/dynamic ROC curves.FEV1 is a better predictor of 5-year survival
(p,0.005).
doi:10.1371/journal.pone.0089866.g005
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in the proposed values.[3,11] To the best of our knowledge, the
present study is the first in which the different recommended
thresholds were obtained from a cohort study looking for
improved sensitivity and specificity points validated for mortality.
One important observation of our study is that although
patients with lower levels of FEV1 (,35%) had a mortality that
was 6 times higher than the patients with better FEV1 ($75%), 5-
year survival of patients with worse FEV1 (%) is almost 50%. In
other words, higher values of FEV1 are associated with lower
mortality, but a low FEV1, even below 35% predicted, does not
exclude prolonged survival. These data are consistent with
previous studies and highlight the conclusion that isolated FEV1
should not be used as an exclusive predictor of prognosis.[23,34]
Accordingly, the new multicomponent indices have shown better
predictive capacity for survival than FEV1 alone. The two common
variables included in all multidimensional prognostic indices in
COPD are respiratory function – measured with postbronchodilator
FEV1 (%)– and dyspnea.[4,6,7,9] However the cutoffs used are
different among them. BODE index uses the old ATS values ($65%,
50–64% 36–49%, and #35%), while the DOSE index uses a
different cutoff ($50%, 30–49%, and,30%), and the updated ADO
index a 5 point scale ($81%, $65–80, $50–64, $36–49 and
#35%).[35] In contrast, the new GOLD document preserves its
previous cutoffs for FEV1 (mild$80%, moderate 50–79%, severe 30–
49%, and very severe,30%), together with a combined COPD risk
assessment evaluated with previous spirometric classification divided
into 2 groups (FEV1%$50% and #49%) along with the individual
patient history of exacerbations in the preceding year (0–1 and$2 or
1 severe exacerbation). The evaluation of symptoms is measured with
the COPD Assessment Test (CAT) (CAT,10 and CAT$10) or
dyspnea assessed by the mMRC scale (0–1 and $2), although the
classification of COPD produced by the mMRC and CAT scores
may differ.[3,29] Additionally, several groups have demonstrated that
the new GOLD multidimensional system classification does not
improve prognostic reliability compared with the previous classifica-
tion based only on spirometric severity for the prediction of mortality
and hospitalizations. Indeed, mortality at 3 years was higher in
GOLD group B (more symptoms, less risk) than in group C (more
risk, fewer symptoms).[17,36–38] A possible explanation is that
patients in group B have more comorbidities, and therefore more
symptoms despite better spirometric values.[39–40]
In the present study, the best cutoff for mMRC dyspnea scale was
the same as that proposed in GOLD multidimensional system
(mMRC#1 or $2), and this confirmed that dyspnea is an excellent
prognostic predictor of survival. In patients with lower levels of
dyspnea, overall survival at 5 years was 75.6% while patients with
higher levels of dyspnea survival decreased to 56.0%. However our
study contradicts the findings reported by Nishimura et al. who
reported that dyspnea is a better predictor of 5-year survival than
airway obstruction in patients with COPD.[15] The most plausible
reason for this discrepancy is that Nishimura’s study was based on
only 183 patients with severe impairment of FEV1 (mean 41%), while
COCOMICS includes many more patients with a wider range of
FEV1 values.
In our study, the predictive ability of FEV1 for 5-year mortality
was similar between genders, but the relationship between FEV1
values and survival was different between patients younger than 65
years and those that were older. In younger patients, mortality was
similar for values of FEV1 between 75% and 100%, drawing an
initial curved plateau, with a progressively decreasing survival
below these values. In elderly patients ($65 years), we observed an
inverse progressive relationship between mortality and lung
function. Elderly patients also had more comorbidities and higher
mortality during follow-up. The importance of comorbidities in
COPD patients and their prognostic implications have been
increasingly recognized in the last decade.[41–43] Heart disease,
lung cancer, hypertension, musculoskeletal disorders, and diabetes,
among many other diseases, are common in COPD patients, and
several epidemiological studies have shown that lung function
impairment is associated with an increased risk of comorbid
diseases.[44] Previous studies highlighted how comorbidities were
more closely related with mortality in older patients, while
pulmonary function seemed to be more important in younger
patients.[14] Several of these comorbidities affect spirometric
values, diabetes and metabolic syndrome, and can lead to a
somewhat restrictive pattern, with significantly lower FEV1 and
FVC values than in non-diabetics, even after adjustment for age,
sex, BMI, smoking status, diabetes duration, and HbA1c levels.
Similarly heart failure, coronary artery disease, osteoporosis,
hypertension, atrial fibrillation, and muscular or hormonal
disorders are related with a reduced forced expiratory volume in
spirometry.[45–48] However, all our patients met criteria for a
pulmonary obstruction pattern, and decreased FEV1 is a
recognized predictor of mortality not only in COPD but also in
other diseases, and even in the general population.[49]
Our study has several strengths and limitations. Among the former
are the large number of subjects included and the long follow-up
period, including nearly 16,000 person-yrs. Both are essential to study
mortality in a broad spectrum of COPD severity. Second, the follow-
up information is very accurate, with few participants lost in follow-
up. Third, all cohorts were recruited in Spain, and all investigators
followed the same COPD clinical guidelines for pharmacological and
non-pharmacological treatment.
However, several limitations need to be acknowledged. Firstly, the
variables studied were measured at inclusion from each patient and
our analyses assumed that the patients’ condition did not change from
baseline. It was not possible to make an analysis of time-dependent
variables to assess changes in medication, smoking habits and other
factors. Although some COPD variables show stability and repeat-
ability, these analyses had no regular monitoring and re-staging.
Secondly, all our participants were Caucasian with a clear
predominance of males, reflecting the epidemiology of COPD in
Spain; therefore, our results should be extrapolated with caution in
other populations.[50]
In conclusion our study performed in a large pooled-analysis of
individual patient-data showed that the new spirometric thresholds
(mild $70%, moderate 56–69%, severe 35–55%, and very severe
#35%) predicted 5-year mortality significantly better than those
used in the GOLD strategy and BODE index, and this
improvement in predictive capacity was also verified in both
short- and long-term follow-up (1 to 10 years).
Acknowledgments
We sincerely thank the PLOS ONE Reviewers for their constructive
criticism and many suggestions that indeed improved our original
submission. We declare that we are open for any re-analyses requested
from PLOS ONE reviewers and readers under the terms established in the
COCOMICS data sharing agreement document. We thank Tom
Yohannan (profesional medical copy-editor) for his editorial assistance.
Author Contributions
Conceived and designed the experiments: PA PMC JBS BC MM.
Performed the experiments: PA PMC JBS BC MM JMM IA CC CE JJSC
JPdT. Analyzed the data: PMC. Wrote the paper: PA PMC JBS BC MM
JMM IA CC CE JJSC JPdT.
FEV1 Cut-Offs and Mortality in COPD Patients
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e89866
References
1. Murray CJ, Vos T, Lozano R, Naqhavi M, Flaxman AD, et al (2012) Disability-
adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-
2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet
380:2197–223.
2. Lozano R, Naghavi M, Foreman K, Kim S, Shibuya K, et al (2012) Global and
regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a
systematic analysis for the Global Burden of Disease Study 2010. 380:2095–128.
3. Vestbo J, Hurd SS, Agustı´ AG, Jones PW, Vogelmeier C, et al (2013) Global
strategy for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med
187:347–65.
4. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, et al (2004).The
body-mass index, airflow obstruction, dyspnea, and exercise capacity index in
chronic obstructive pulmonary disease. N Engl J Med 350:1005–1012.
5. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, et al (1999) Usefulness of
the Medical Research Council (MRC) dyspnoea scale as a measure of disability
in patients with chronic obstructive pulmonary disease. Thorax 54:581–586.
6. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MO, Sanchez
PR (2009) Severe exacerbations and BODE index: two independent risk factors
for death in male COPD patients. Respir Med 103:692–699.
7. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, et al (2009)
Expansion of the prognostic assessment of patients with chronic obstructive
pulmonary disease: the updated BODE index and the ADO index. Lancet
374:704–711.
8. Azarisman MS, Fauzi MA, Faizal MP, Azami Z, Roslina AM, et al (2007) The
SAFE (SGRQ score, air-flow limitation and exercise tolerance) index: a new
composite score for the stratification of severity in chronic obstructive pulmonary
disease. Postgrad Med J 83:492–497.
9. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, et al
(2009) Derivation and validation of a composite index of severity in chronic
obstructive pulmonary disease – the dose index. Am J Respir Crit Care Med
180:1189–1195.
10. Marin JM, Alfageme I, Almagro P, Casanova C, Esteban C, et al (2013)
Multicomponent indices to predict survival in COPD: The COllaborative
COhorts to assess multicomponent indices of COPD in Spain-COCOMICS
study. Eur Respir J 42:323–32.
11. BTS guidelines for the management of chronic obstructive pulmonary disease
(1997) The COPD Guidelines Group of the Standards of Care Committee of the
BTS. Thorax 52 Suppl 5:S1–28.
12. Miravitlles M, Soler-Catalun˜a JJ, Calle M, Molina J, Almagro P, et al. (2012)
Pharmacological treatment of stable COPD. Arch Bronconeumol 48: 247–257
13. Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of
patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J
23:932–946.
14. Burgel PR, Paillasseur JL, Peene B, Dusser D, Roche N, et al (2012) Two distinct
chronic obstructive pulmonary disease (COPD) phenotypes are associated with
high risk of mortality. PLoS One 7:e51048.
15. Nishimura K, Izumi T, Tsukino M, Oga T (2002) Dyspnea is a better predictor
of 5-year survival than airway obstruction in patients with COPD. Chest
121:1434–40.
16. Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K (2012) Analysis of
longitudinal changes in dyspnea of patients with chronic obstructive pulmonary
disease: an observational study. Respir Res 13:85.
17. Soriano JB, Alfageme I, Almagro P, Casanova C, Esteban C, et al (2013)
Distribution and prognostic validity of the new global initiative for chronic
obstructive lung disease grading classification. Chest 143:694–702.
18. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, et al (2008)
Predictors of mortality in patients with stable COPD. J Gen Intern Med
23:1829–34.
19. de Torres JP, Bastarrika G, Zagaceta J, Sa´iz-Mendiguren R, Alcaide AB, et al
(2011) Emphysema presence, severity, and distribution has little impact on the
clinical presentation of a cohort of patients with mild to moderate COPD. Chest
139:36–42.
20. Soler-Catalun˜a JJ, Martı´nez-Garcı´a MA, Roma´n Sa´nchez P, Salcedo E,
Navarro M, et al (2005) Severe acute exacerbations and mortality in patients
with chronic obstructive pulmonary disease. Thorax 60:925–31.
21. Alfageme I, Reyes N, Merino M, Reina A, Gallego J, et al (2010) The effect of
airflow limitation on the cause of death in patients with COPD. Chron Respir
Dis 7:135–45.
22. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, et al (2005)
Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 171:591–7.
23. Almagro P, Calbo E, Ochoa de Echagu¨en A, Barreiro B, Quintana S, et al
(2002) Mortality after hospitalization for COPD. Chest 121:1441–8.
24. Sanjaume M, Almagro P, Rodrı´guez-Carballeira M, Barreiro B, Heredia JL, et
al (2009) Post-hospital mortality in patients re-admitted due to COPD. Utility of
BODE index.Rev Clin Esp 209:364–70.
25. Almagro P, Salvado´ M, Garcia-Vidal C, Rodrı´guez-Carballeira M, Cuchi E, et
al (2012) Pseudomonas aeruginosa and mortality after hospital admission for
chronic obstructive pulmonary disease. Respiration 84:36–43.14
26. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR (2010) Outcomes in
patients with chronic obstructive pulmonary disease and obstructive sleep apnea:
the overlap syndrome. Am J Respir Crit Care Med 182:325–31.
27. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al (2005)
Standardisation of spirometry. Eur Respir J 26:319–338.
28. Charlson ME, Szatrowski TP, Peterson J, Gold J (1994) Validation of a
combined comorbidity index. J Clin Epidemiol 47:1245–1251.
29. Cox DR, Oakes D (1984) Analysis of Survival Data. London, England:
Chapman & Hall.
30. Heagerty PJ, Zheng Y (2005) Survival model predictive accuracy and ROC
curves. Biometrics 61:92–105.
31. Martı´nez-Camblor P, Corral N (2012) A general bootstrap algorithm for
hypothesis testing. J Statist Plann Inference 142:589–600.
32. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, et al (1996) Impaired
lung function and mortality risk in men and women: findings from the Renfrew
and Paisley prospective population study. BMJ 313:711–5.
33. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, et al (2011) Changes in
forced expiratory volume in 1 second overtime in COPD. N Engl J Med
365:1184–92.
34. Postma DS, Sluiter HJ (1989) Prognosis of chronic obstructive pulmonary
disease: the Dutch experience. Am Rev Respir Dis 140:S100–5.
35. Puhan MA, Hansel NN, Sobradillo P, Enright P, Lange P, et al (2012) Large-
scale international validation of the ADO index in subjects with COPD: an
individual subject data analysis of 10 cohorts. BMJ Open 2.e002152.
36. Kim S, Oh J, Kim YI, Ban HJ, Kwon YS, et al (2013) Differences in
classification of COPD group using COPD assessment test (CAT) or modified
Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses.
BMC Pulm Med 13:35.
37. Johannessen A, Nilsen RM, Storebø M, Gulsvik A, Eagan T, et al (2013)
Comparison of 2011 and 2007 GOLD Guidelines for Predicting Mortality and
Hospitalization. Am J Respir Crit Care Med 188:602–8
38. Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, et al (2012)
Prediction of the Clinical Course of Chronic Obstructive Pulmonary Disease,
Using the New GOLD Classification. Am J Respir Crit Care Med 186:975–981.
39. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, et al (2013)
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the
ECLIPSE cohort. Eur Respir J. 42:636–46.
40. Dı´ez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, Lopez-Garcia F,
et al (2013) COPD patients with and without metabolic syndrome: clinical and
functional differences. Intern Emerg Med [Epub ahead of print]
41. Clini EM, Beghe´ B, Fabbri LM (2013) Chronic obstructive pulmonary disease is
just one component of the complex multimorbidities in patients with COPD.
Am J Respir Crit Care Med 187:668–71.
42. Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso-Ortiz B, et al (2012).
Comorbidities and short-term prognosis in patients hospitalized for acute
exacerbation of COPD. The ESMI study. Chest 142:1126–33.
43. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, et al (2013)
Clusters of comorbidities based on validated objective measurements and
systemic inflammation in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 187:728–35.
44. Mu¨llerova H, Agusti A, Erqou S, Mapel DW (2013) Cardiovascular comorbidity
in chronic obstructive pulmonary disease: systematic literature review. Chest
144:1163–78.
45. Yu D, Simmons D (2013) Association between lung capacity measurements and
abnormal glucose metabolism: findings from the Crossroads study. Diabet Med
[Epub ahead of print]
46. Nourizadeh M, Ghelich Y, Amin A, Eidani E, Gholampoor Y, et al (2013) Study
the mechanical pulmonary changes in patients with congestive heart failure
(CHF) by impulse oscillometry. J Cardiovasc Dis Res 4:130–3.
47. Moayyeri A, Bingham SA, Luben RN, Wareham NJ, Khaw KT (2009)
Respiratory function as a marker of bone health and fracture risk in an older
population. J Bone Miner Res 24:956–63.
48. Johnson LS, Juhlin T, Engstro¨m G, Nilsson PM (2013) Reduced forced
expiratory volume is associated with increased incidence of atrial fibrillation: the
Malmo Preventive Project. Europace [Epub ahead of print]
49. Baughman P, Marott JL, Lange P, Martin CJ, Shankar A, et al (2012) Combined
effect of lung function level and decline increases morbidity and mortality risks.
Eur J Epidemiol 27:933–43.
50. Miravitlles M, Soriano JB, Garcı´a-Rı´o F, Mun˜oz L, Duran-Tauleria E, et al
(2009) Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality
of life and daily life activities. Thorax 64:863–868.
FEV1 Cut-Offs and Mortality in COPD Patients
PLOS ONE | www.plosone.org 7 February 2014 | Volume 9 | Issue 2 | e89866
